Abstract：Objective To investigate the clinical effect of Valsartan Hydrochlorothiazide in the treatment of patients with cerebral-cardiac syndrome.Methods A total of 90 cases of patients diagnosed with cerebral-cardiac syndrome admitted to our hospital from January 2016 to January 2019 were selected as the research objects, who were divided into treatment group (45 cases) and control group (45 cases) according to random number table method，the control group was treated by regular treatment,the treatment group was treated by regular treatment combined with Valsartan Hydrochlorothiazide.The clinical efficacy, electrocardiograph (ECG) improvement, C-reactive protein (CRP), tumor necrosis factor(TNF-α) and interleukin-6 (IL-6) levels before and after treatment were compared between the two groups.Results The total effective rate and the ECG effective rate of the treatment group were higher than those of the control group,and the levels of CRP, IL-6 and TNF-α in the treatment group were lower than those of the control group, the differences were statistically significant(P<0.05).Conclusion Valsartan Hydrochlorothiazide can significantly reduce the CRP,TNF-α and IL-6 levels, which can improve the clinical curative effect of patients with cerebral-cardiac syndrome.
马超； 王诚高； 袁文金. 缬沙坦氢氯噻嗪治疗脑心综合征患者的临床效果[J]. 中国当代医药, 2020, 27(12): 129-131转135.
MA Chao； WANG Cheng-gao； YUAN Wen-Jin. Clinical effect of Valsartan Hydrochlorothiazide in the treatment of patients with cerebral-cardiac syndrome. 中国当代医药, 2020, 27(12): 129-131转135.
Idkaidek N，Agha N，Arafat T.Saliva versus plasma bioequivalence of valsartan/hydrochlorothiazide in humans：validation of classesⅡand Ⅳdrugs of the salivary excretion classification system[J].Drug Res，2018，68（1）：54-59.
京公网安备 11010502046607号